DUBLIN–(BUSINESS WIRE)–The “Myeloproliferative Neoplasm Drugs Market – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027” report has been added to ResearchAndMarkets.com’s offering.
Myeloproliferative neoplasms (MPNs) are a type of rare blood cancers, which leads to production of excess red blood cells, white blood cells, or platelets in the bone marrow of individuals.
Myelo refers to bone marrow and spinal cord of the individual and proliferative describes the rapid growth of blood cells, whereas neoplasm describes the abnormal and uncontrolled growth of cells in patients. The overproduction of blood cells is often associated with a somatic mutation, for example, the over production of JAK2 (Janus kinase 2) leads to chronic myeloproliferative disorders. The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
Market Dynamics
Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth. For instance, in January 2019, Takeda Pharmaceutical Company Limited acquired Shire Inc (a biopharmaceutical company in U.K.),to expand its geographical presence in the market and enhance its product portfolio through research and development activities.
Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market. For instance, in November 2018, Pfizer Inc. received the U.S. Food and Drug Administration approval for Daurismo for use in adults with acute myeloid leukemia (AML) in 75 years or older patients.
Furthermore, in December 2017, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for a supplemental New Drug Application (sNDA) to expand the indication of BOSULIF (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Key features of the study:
- This report provides in-depth analysis of the global myeloproliferative neoplasm drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
- It profiles leading players in the global myeloproliferative neoplasm drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global myeloproliferative neoplasm drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global myeloproliferative neoplasm drugs market
Company Profiles
- Novartis International AG.
- Bristol – Myers Squibb
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Incyte
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche AG
- Gamida Cell
- Sierra Oncology, Inc.
- CTI BioPharma Corp.
- Imago BioSciences
- AbbVie Inc.
- Constellation Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/pwuo2q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900